Phase 1b trial

CAMBRIDGE, Mass., July 28, 2026 ProMIS Neurosciences Inc. announced positive blinded six-month interim safety and biomarker data from the...

SAN DIEGO – July 27, 2026 Kura Oncology, Inc. has reported updated Phase 1a clinical data from the ongoing...

London, UK – July 24, 2026 Persica Pharmaceuticals has presented new scientific analyses supporting the development of its investigational...

Serina Therapeutics, Huntsville, Ala., July 23, 2026 Serina Therapeutics announced the successful completion of enrollment and dosing in Cohort...

LAUSANNE, Switzerland, June 30, 2026 ADC Therapeutics SA has announced the successful completion of patient enrollment in the LOTIS-7...

ROCKVILLE, Maryland, June 2, 2026 Rise Therapeutics announced the completion of full enrollment in the four-week dose expansion cohort...

SOUTH SAN FRANCISCO, Calif., June 3, 2026 Tenaya Therapeutics announced new interim data from its ongoing MyPEAK™-1 Phase 1b/2...

AUSTIN, Texas | May 30, 2026 PanTher Therapeutics announced the completion of the dose-escalation portion of its Phase 1b...

SOUTH SAN FRANCISCO, Calif., May 7, 2026 TRexBio announced new late-breaking translational and preclinical data supporting TNFR2 agonism as...

EMERYVILLE, Calif., May 6, 2026 Totus Medicines announced encouraging interim Phase 1b clinical data for its investigational therapy TOS-358...